HIMS slides nearly 7% amid bearish technical signals and high short interest

Traders Union
All News
Stocks
Hims & hers health slides 6.64% today

Highlights

Hims & Hers Health is projected to report third-quarter revenue of $892 million, up 49% year-over-year.
The company expanded its Eli Lilly partnership to offer FDA-approved weight-loss drugs Zepbound and Foundayo on its telehealth platform.
Shares of Hims & Hers Health trade below key moving averages with negative momentum signals, and are expected to fluctuate between $21.44 and $27.1 over the next five days.

Revenue optimism muted by high short interest and partnership shift

Hims & Hers Health is scheduled to report its third-quarter earnings after the close on Monday, with analysts forecasting around $892 million in revenue, an increase of approximately 49% year-over-year. The company recently expanded its partnership with Eli Lilly to give patients access to weight-loss drugs Zepbound and Foundayo on its telehealth platform, replacing compounded alternatives with branded, FDA-approved options. High short interest remains at 23%, and prior quarters showed strong revenue growth, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees sustained technical weakness in Hims & Hers Health. The stock trades below all major moving averages and faces strong bearish momentum. Short interest at 23% amplifies downside risk, while recent news on branded drug access has failed to boost sentiment. He remains wary of a false stabilisation, noting bearish signals from multiple indicators. "The technical landscape remains unfavorable, and I would remain defensive until a meaningful break above $24.57 confirms a reversal."

Viktoras Karapetjanc, expert at Traders Union, remains constructive on Hims & Hers Health despite current volatility. He highlights exceptional revenue growth and the strategic partnership with Eli Lilly as positive fundamentals. The ongoing shift to approved weight-loss drugs expands future opportunities. Karapetjanc believes near-term weakness is typical ahead of earnings and expects renewed upside from these strong core drivers. "With robust fundamentals and further growth in telehealth adoption, I see multiple setups for a bullish recovery beyond $24.57."

Sholanke Dele, market strategist, points to eroding sentiment and ongoing selling pressure. He notes weak price action despite recent news and upcoming earnings. Elevated short interest signals persistent skepticism among traders. "Volatility is likely to persist, and unless sentiment shifts dramatically, I remain cautious on HIMS in the near term."

Bearish momentum persists as technical boundaries cap recovery

Hims & Hers Health is trading below its 20-day, 50-day, and 200-day moving averages (MA-20: $27.94, MA-50: $28.43, MA-200: $26.91), indicating short-, medium-, and long-term downside momentum. The near-term ceiling stands at $24.57, while the floor is set at $22.95, and additional resistance is confirmed by the distant moving averages and the Ichimoku Kijun at $27.34. Momentum indicators remain negative: the MACD is bearish at -1.25, and the Average Directional Index (ADX) at 14.16 suggests a weak trend. The Relative Strength Index (RSI) and Stochastic RSI are neutral, while the Commodity Channel Index (CCI) is oversold at -141.09, pointing to possible selling exhaustion. Bull/Bear Power (BBP) is negative and the Awesome Oscillator signals selling pressure, reinforcing the prevailing bearish tone. The price is near the intraday low with notable volatility at 6.76%.

Earlier, analysts noted that Hims & Hers faced mixed technical signals and potential sideways trading, even as new pharmaceutical partnerships offered a possible long-term catalyst. The latest developments reinforce downside pressure and elevate the importance of support at $22.95, which traders should monitor closely for signs of either stabilization or further breakdown.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.